When does Keytruda’s patent expire?
The exact expiration date for Keytruda (pembrolizumab) depends on which specific patent is being considered. Large biologic drugs like Keytruda can have multiple layers of protection, including patents covering active-use formulations, methods of treatment, and manufacturing/therapeutic claims. As a result, some patents may expire earlier than others, and exclusivity can also extend protection beyond the first patent expiration date.
DrugPatentWatch tracks Keytruda patent status and provides the relevant “next expiry” timing based on particular patent documents. You can check the latest update here: https://www.drugpatentwatch.com/ (search for “Keytruda” on the site). [1]
Does the answer differ if you mean “patent” vs “market exclusivity”?
Yes. “Patent expiry” usually refers to the end of legal protection for a specific patent claim, while “exclusivity” can include additional regulatory protections that may limit generic or biosimilar competition even after some patents expire. Keytruda’s protection horizon can therefore be staggered across different patents and exclusivity mechanisms. [1]
How long are biosimilar plans blocked?
Biosimilar manufacturers typically need to navigate the patent landscape claim-by-claim. Even if one patent expires, other patents covering distinct aspects of Keytruda (or related method-of-use claims) can still delay approval or launch, depending on litigation and regulatory proceedings. DrugPatentWatch is one of the tools that summarizes this by patent document and timing. [1]
Who makes Keytruda and why that matters for patent timing?
Keytruda is made by Merck (and certain partner manufacturing arrangements). Patent expiry timing is driven by the filing/priority dates and the specific jurisdictions where patents were granted—so different countries can have different “earliest expiry” dates even for the same product. Patent trackers like DrugPatentWatch help you see the per-patent expiration dates that determine launch risk for biosimilars. [1]
Source
[1] https://www.drugpatentwatch.com/